Background: The regional chronomodulated hepatic arterial infusion chemotherapy (HAIC) is an effective regimen for the treatment of patients with unresectable liver metastases from colorectal cancer, especially for the conversion into resectability. Aim: To demonstrate that chronomodulated HAI triplet chemotherapy according to OPTILIV protocol is well tolerated and displayed high antitumor activity in this heavily-pretreated patient. Case Presentation: A 54 years old patient from Russia was treated for a tumor in the ascending colon presented with 13 hepatic metastases ranging from 0.3 to 2.7 cm in diameter. He underwent a laparoscopic right hemicolectomy, 12 cycles of FOLFIRINOX combined to bevacizumab for the last 5 cycles, resulting in a partial response according to CT scan. It was decided to perform a two-stage hepatectomy at Paul Brousse hospital: left partial hepatectomy allowed the excision of 9 lesions. Radio frequency ablation was performed in 2 nodular lesions. Afterwards, the patient received 5 cycles of chronomodulated triplet chemotherapy into the hepatic artery, according to the OPTILIV protocol design, yet without cetuximab, because of the KRAS mutation in the liver metastases, with a partial response. The patient could then undergo the second stage of the planned right hepatectomy, which turned out to be an R0 How to cite this paper:
Introduction
Worldwide, liver metastases develop in nearly 60% of the patients with colorectal carcinoma [1] . The vast majority (80% -90%) of patients present with unresectable liver metastases, and 5-year survival rate in these patients can range from 25% -35% [2] [3] . The potential value of hepatectomies for achieving long-term survival in patients with initially non-resectable colorectal liver metastases (CLM) has resulted in the development of liver-targeted oncological strategies [4] . Hepatic-arterial infusion chemotherapy (HAIC) has been developed to ensure a greater locoregional exposure to cytotoxic agents. HAIC induces significantly higher response rates (RR) than systemic chemotherapy [5] [6] [7] [8] [9] . A 5-year survival rate of 33% has been achieved after conversion hepatectomy and cure could be achieved in 16% of patients with initially unresectable CLM after effective downsizing chemotherapy [10] . Such liver-directed chemotherapy could benefit further from adjustment of drug-delivery pattern to the circadian clock in healthy hepatocytes [11] . Nevertheless, a large, randomized trial as well as a meta-analysis of three randomized trial comparing chronotherapy vs. conventional delivery of oxaliplatin-5-fluorouracil-leucovorin using individual dose escalation revealed a survival advantage in men but not in women. These results suggested the deleterious effect of dose intensification on 
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Discussion
It has been demonstrated here, that chronomodulated HAI triplet chemotherapy according to OPTILIV protocol was well tolerated and displayed high antitumor activity in this heavily-pretreated patient, allowing to achieve an objective response despite prior progression on FOLFIRINOX (the same triplet chemo by IV route) [14] [15]. This strategy permitted to overcome drug resistance and to perform further complete resection of the liver metastases with prolonged patient survival. The OPTILIV trial (irinotecan, 5-FU and oxaliplatin being given into the hepatic artery and cetuximab intravenously) is prospective international trial, whose primary end point is the conversion of initially uncontrolled and/or unresectable CLM to resection. The main end point was met, achieving a complete macroscopic resection rate of CLM in nearly 30% of all included patients with initially unresectable CLM [14] . Moreover, subgroup analysis suggested that the survival benefit from the liver-targeted chemo-surgery strategy was largely better in the patients receiving irinotecan, oxaliplatin and 5-FU as a chronomodulated hepatic artery infusion [16] . Several recent studies have reported that patients with right-sided primary tumours have worse survival outcomes and it is possible that these patients benefit less from standard therapies survival of 62 months [20] . In a recent study, the results from the phase-II clinical trial show that selected patients with strictly defined unresectable CRLM, despite pre-treatment with systemic chemotherapy and unfavorable oncologic characteristics, can experience enough response after combination treatment with HAI and systemic therapy to become resectable. Combination of HAI and systemic therapy resulted in very high response rates in both previously treated (72%) and chemotherapy-naïve patients (82%); overall 8% CR (4 patients). The primary endpoint of the study (conversion to resection) was achieved with 47% of patients undergoing complete resection. Among the whole cohort, OS was 38 months, and one and 3-year survival rates were 92% and 55%, respectively [3] . Despite the inefficiency of nivolumab in this case, initial analysis of nivolumab plus ipilimumab in patients with ≥6 months follow-up demonstrated a manageable safety profile and clinical activity characterized by a 55% overall response rate and 80% disease control rate in patients with DNA mismatch repair-deficient (dMMR)/microsatellite instability-high (MSI-H) mCRC [21] . The ineffectiveness of nivolumab in this case may be due to the extensive heterogeneity in microsatellite unstable (MSI) between primary tumor and metastases, which has been recently shown in colorectal tumours [22] . Soimmunotherapy role even in patients with MSI status is not a landmark of response to anti-PD1 agents.
A pivotal phase 2 study by Le et al. highlighted the importance of mismatch-repair deficiency and/or (MSI-H) profiles in prediction of the clinical benefit of immune checkpoint blockade with pembrolizumab (anti-PD-1 drug) [23] . Moreover, the U.S. Food and Drug Administration (FDA) granted accelerated approval to anti-PD-1 drug pembrolizumab for adult and pediatric patients with unresectable/metastatic MSI-H/MMR deficient solid tumors (regardless the histotype) that have progressed following prior treatment and without satisfactory alternative treatment modalities. The approval also covered MSI-H CRC patients who progressed following treatment with a classic cytotoxic therapy (fluoropyrimidine, oxaliplatin, and irinotecan) [24] .
Taken together, this literature review suggests that cure can be achieved in patients with initially unresectable CLM after the administration of the most effective downsizing chemotherapy, especially as first of second line. The patients with extensive unresectable CRLM, the majority of whom were previously treated, are able to undergo complete resection after HAI. Conversion to resection is associated with prolonged survival. The identification of optimum sequence of application of chronomodulated HAIC, immune checkpoint inhibitors, metastases surgery could increase the survival and possibly cure rate in these patients. Thus, chronomodulated HAI is useful in patients with liver metastases from colorectal cancer and deserves to be further assessed prospectively in clinical trials chemotherapy.
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